Sotera Health Company (NASDAQ:SHC) Given Average Rating of "Moderate Buy" by Brokerages

Key Points

• Sotera Health Company (NASDAQ:SHC) is currently rated as a "Moderate Buy" by five brokerages, with a consensus price target of $16.00.
• The company reported earnings of $0.20 per share, surpassing analysts' expectations of $0.17, with a revenue of $294.34 million for the quarter.
• Recent analyst actions include upgrades from Goldman Sachs and Wall Street Zen, which have increased their rating on Sotera Health to "buy" and "strong-buy", respectively.

Sotera Health Company (NASDAQ:SHC - Get Free Report) has earned an average rating of "Moderate Buy" from the five brokerages that are currently covering the firm, Marketbeat reports. One analyst has rated the stock with a hold recommendation and four have assigned a buy recommendation to the company. The average 12 month target price among brokerages that have covered the stock in the last year is $16.00.

A number of brokerages recently issued reports on SHC. Wall Street Zen upgraded Sotera Health from a "buy" rating to a "strong-buy" rating in a research note on Saturday, August 16th. The Goldman Sachs Group upgraded Sotera Health from a "neutral" rating to a "buy" rating and lifted their price objective for the company from $14.00 to $17.00 in a research note on Monday, May 5th. Finally, Barclays reiterated an "overweight" rating on shares of Sotera Health in a research note on Friday, August 8th.

Insider Buying and Selling at Sotera Health

In other Sotera Health news, insider Michael P. Rutz sold 126,611 shares of Sotera Health stock in a transaction dated Friday, August 22nd. The stock was sold at an average price of $16.38, for a total transaction of $2,073,888.18. Following the completion of the transaction, the insider owned 450,204 shares in the company, valued at approximately $7,374,341.52. This trade represents a 21.95% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Insiders own 55.12% of the company's stock.

Hedge Funds Weigh In On Sotera Health

Institutional investors and hedge funds have recently modified their holdings of the business. TPG GP A LLC acquired a new stake in Sotera Health in the 1st quarter worth about $79,126,000. Sculptor Capital LP acquired a new stake in Sotera Health in the 4th quarter worth about $68,400,000. Two Seas Capital LP boosted its holdings in Sotera Health by 624.0% in the 4th quarter. Two Seas Capital LP now owns 2,896,136 shares of the company's stock worth $39,619,000 after buying an additional 2,496,136 shares during the last quarter. D. E. Shaw & Co. Inc. boosted its holdings in Sotera Health by 140.8% in the 4th quarter. D. E. Shaw & Co. Inc. now owns 2,624,750 shares of the company's stock worth $35,907,000 after buying an additional 1,534,666 shares during the last quarter. Finally, Ananym Capital Management LP acquired a new stake in Sotera Health in the 4th quarter worth about $13,680,000. Hedge funds and other institutional investors own 91.03% of the company's stock.

Sotera Health Stock Up 0.1%

Shares of Sotera Health stock traded up $0.01 during trading on Thursday, reaching $16.40. The company's stock had a trading volume of 1,513,353 shares, compared to its average volume of 1,651,989. The company has a quick ratio of 2.23, a current ratio of 2.47 and a debt-to-equity ratio of 4.49. The company has a market cap of $4.66 billion, a price-to-earnings ratio of 205.03 and a beta of 1.81. Sotera Health has a 1-year low of $9.53 and a 1-year high of $17.08. The company has a 50-day simple moving average of $12.56 and a two-hundred day simple moving average of $12.20.

Sotera Health (NASDAQ:SHC - Get Free Report) last issued its earnings results on Friday, August 8th. The company reported $0.20 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.17 by $0.03. The company had revenue of $294.34 million during the quarter, compared to analyst estimates of $275.81 million. Sotera Health had a return on equity of 39.42% and a net margin of 2.14%.The firm's quarterly revenue was up 6.4% on a year-over-year basis. During the same quarter last year, the business posted $0.19 EPS. Sotera Health has set its FY 2025 guidance at 0.750-0.820 EPS. As a group, equities analysts forecast that Sotera Health will post 0.61 earnings per share for the current year.

About Sotera Health

Sotera Health Company engages in the provision of sterilization, lab testing, and advisory services in the United States and internationally. The company operates through three segments: Sterigenics, Nordion, and Nelson Labs. It provides mission-critical end-to-end sterilization services, including gamma and electron beam irradiation, and ethylene oxide processing, as well as designs, installs, and maintains gamma irradiation systems.